LENZ LENZ Therapeutics, Inc.

$6.15 -2.54%

Healthcare · Biological Products, (No Diagnostic Substances)

LENZ Therapeutics, Inc. (LENZ) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $193 million. Shares last traded at $6.15, 87.9% below their 52-week high. Over the past year the stock is down 78.8%. Net profit margin is -430.3%, below the peer median of 6.3%.

Market Cap

$193M

Shares Out

31.4M

EPS (TTM)

$-4.56

P/E Ratio

—

P/S Ratio

10.10

P/B Ratio

0.78

Dividend / Share

—

Dividend Yield

—

52-Week High

$50.85

52-Week Low

$5.85

Volume

40,393

Avg Vol (3m)

44,353.127

Performance

-5.09%

-7.24%

-46.59%

-63.22%

YTD

-61.61%

-78.78%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

31.91

SMA (50)

$8.22

SMA (200)

$20.05

Price vs SMA50

-25.23%

Price vs SMA200

-69.33%

ATR (14)

$0.50

Financials

Revenue

$19M

Net Income

$-82M

Gross Margin

—

Operating Margin

-477.5%

Net Margin

-430.3%

Return on Equity

-33.3%

Return on Assets

-30.1%

Current Ratio

10.40

Debt / Equity

0.11

Revenue Growth (YoY)

—

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

Period	EPS (diluted)	Reported
Q1 2026	$-1.32	2026-05-11
FY 2025	$-2.85	2026-03-24
Q3 2025	$-1.65	2025-11-05
Q2 2025	$-1.06	2025-07-30
Q1 2026	$-0.53	2026-05-11
FY 2025	$-2.34	2026-03-24

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

LENZ vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers

10.10 / 5.21 med

+94% premium

Net margin vs peers

-430.3% / 6.3% med

below median

1–14 of 14


AMGN	Amgen	$182.1B	23.62	4.96	21.0%	-1.27%
GILD	Gilead Sciences	$153.5B	18.04	5.21	28.9%	-1.46%
RVMD	Revolution Medicines, Inc.	$34.6B	-30.62	—	—	+3.14%
BIIB	Biogen	$29.0B	22.44	2.93	13.1%	-1.15%
MRNA	Moderna	$25.4B	-8.99	—	—	+3.22%
NBIX	Neurocrine Biosciences Inc	$15.9B	33.24	5.56	16.7%	-0.48%
EXEL	Exelixis, Inc.	$13.1B	16.68	5.62	33.7%	-1.04%
KRYS	Krystal Biotech, Inc.	$10.2B	50.02	26.33	52.6%	+1.68%
TECH	Bio-Techne	$9.1B	123.61	7.44	6.0%	+5.36%
HALO	Halozyme Therapeutics, Inc.	$8.1B	25.67	5.82	22.7%	-0.03%
IBRX	Immunitybio, Inc.	$7.7B	-21.87	—	—	+5.01%
RGEN	Repligen Corp	$7.4B	152.27	10.08	6.6%	-1.20%
KYMR	Kymera Therapeutics, Inc.	$7.4B	23.88	—	—	+0.44%
PCVX	Vaxcyte, Inc.	$7.4B	-9688.00	—	—	+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.